東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Evidence-biased antidepressant presc...

SpringerLink (Online service)

Linked to FindBook

Google Book

Amazon

博客來

Evidence-biased antidepressant prescription = overmedicalisation, flawed research, and conflicts of interest /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Evidence-biased antidepressant prescription/ by Michael P. Hengartner.
Reminder of title:	overmedicalisation, flawed research, and conflicts of interest /
Author:	Hengartner, Michael P.
Published:	Cham :Springer International Publishing : : 2022.,
Description:	vii, 354 p. :ill., digital ;24 cm.
[NT 15003449]:	1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform.
Contained By:	Springer Nature eBook
Subject:	Antidepressants. -
Online resource:	https://doi.org/10.1007/978-3-030-82587-4
ISBN:	9783030825874

Evidence-biased antidepressant prescription = overmedicalisation, flawed research, and conflicts of interest /
Hengartner, Michael P.

Evidence-biased antidepressant prescriptionovermedicalisation, flawed research, and conflicts of interest /[electronic resource] :by Michael P. Hengartner. - Cham :Springer International Publishing :2022. - vii, 354 p. :ill., digital ;24 cm.

1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform.

This book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry, and the European Public Health Association.

ISBN: 9783030825874

Standard No.: 10.1007/978-3-030-82587-4doiSubjects--Topical Terms:

922074
Antidepressants.

LC Class. No.: RM332 / .H46 2022

Dewey Class. No.: 616.8527061

Evidence-biased antidepressant prescription = overmedicalisation, flawed research, and conflicts of interest /
LDR:03188nmm a2200325 a 4500 001 2296651
003 DE-He213
005 20211209012340.0
006 m d
007 cr nn 008maaau
008 230324s2022 sz s 0 eng d
020 $a 9783030825874 $q (electronic bk.)
020 $a 9783030825867 $q (paper)
024 7 $a 10.1007/978-3-030-82587-4 $2 doi
035 $a 978-3-030-82587-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM332 $b .H46 2022
072 7 $a MMJ $2 bicssc
072 7 $a PSY007000 $2 bisacsh
072 7 $a MKM $2 thema
082 0 4 $a 616.8527061 $2 23
090 $a RM332 $b .H511 2022
100 1 $a Hengartner, Michael P. $3 3591510
245 1 0 $a Evidence-biased antidepressant prescription $h [electronic resource] : $b overmedicalisation, flawed research, and conflicts of interest / $c by Michael P. Hengartner.
260 $a Cham : $b Springer International Publishing : $b Imprint: Palgrave Macmillan, $c 2022.
300 $a vii, 354 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Introduction: How did I get here? -- 2. Antidepressants in clinical practice -- 3. Medico-cultural context -- 4. Flaws in antidepressant research -- 5. Conflicts of interest in psychiatry -- 6. Solutions for reform.
520 $a This book addresses the over-prescribing of antidepressants in people with mostly mild and subthreshold depression. It outlines the steep increase in antidepressant prescription and critically examines the current scientific evidence on the efficacy and safety of antidepressants in depression. The book is not only concerned with the conflicting views as to whether antidepressants are useful or ineffective in various forms of depression, but also aims at detailing how flaws in the conduct and reporting of antidepressant trials have led to an overestimation of benefits and underestimation of harms. The transformation of the diagnostic concept of depression from a rare but serious disorder to an over-inclusive, highly prevalent but predominantly mild and self-limiting disorder is central to the books argument. It maintains that biological reductionism in psychiatry and pharmaceutical marketing reframed depression as a brain disorder, corroborating the overemphasis on drug treatment in both research and practice. Finally, the author goes on to explore how pharmaceutical companies have distorted the scientific literature on the efficacy and safety of antidepressants and how patient advocacy groups, leading academics, and medical organisations with pervasive financial ties to the industry helped to promote systematically biased benefit-harm evaluations, affecting public attitudes towards antidepressants as well as medical education, training, and practice. Michael P. Hengartner is a senior researcher and lecturer at the Zurich University of Applied Sciences, Switzerland. He has published over 130 peer-reviewed journal articles and four book chapters. He was an expert evaluator for the European Research Council and the World Health Organization and currently is a member of the Swiss School of Public Health, the German Society for Social Psychiatry, and the European Public Health Association.
650 0 $a Antidepressants. $3 922074
650 0 $a Drugs $x Prescribing. $3 564502
650 0 $a Antidepressants $x Effectiveness. $3 3591511
650 1 4 $a Clinical Psychology. $3 891159
650 2 4 $a Psychiatry. $3 517037
650 2 4 $a Medical Sociology. $3 2182151
650 2 4 $a Medical Anthropology. $3 3201428
650 2 4 $a Psychopathology. $3 531107
650 2 4 $a Public Health. $3 624351
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-030-82587-4
950 $a Behavioral Science and Psychology (SpringerNature-41168)